COMMUNIQUÉS West-GlobeNewswire

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

05/11/2024 - 22:15

Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024 Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis (RA) in February [...]

MannKind to Present at 2024 UBS Healthcare Conference

05/11/2024 - 22:15

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products [...]

Anaptys Announces Participation in November and December Investor Conferences

05/11/2024 - 22:15

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president [...]

Cellectis présente de multiples stratégies pour améliorer l'efficacité des cellules CAR T dans les tumeurs solides à la réunion annuelle de la SITC

05/11/2024 - 22:30

NEW YORK, 05 nov. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN® pour développer [...]

Optinose Announces Reporting Date for Third Quarter 2024 Financial Results

05/11/2024 - 22:30

Conference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time YARDLEY, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, [...]

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

05/11/2024 - 22:30

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]

Lifeward to Report Third Quarter Financial Results on November 12, 2024

05/11/2024 - 22:38

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what [...]

Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability

05/11/2024 - 22:43

Tevogen Bio is a fully functional biotech, with investor-valued assets over $10 billion achieved with under $40 million in spending. Approximately 78% of Tevogen Bio's common stock is held by company officers. WARREN, N [...]

La FDA octroie à Merus un report de la date PDUFA pour le zénocutuzumab

05/11/2024 - 23:39

UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 05 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après « Merus », « la Société », « nous » ou « notre/nos », une société du secteur de l’oncologie au stade [...]

Pacific Health Care Organization, Inc. Reports its Third Quarter 2024 Results

05/11/2024 - 18:26

Irvine, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) last Friday filed with the Securities and Exchange Commission (the “Commission”) its quarterly report on [...]

Genmab to Present at Jefferies London Healthcare Conference

05/11/2024 - 19:11

Media Release COPENHAGEN, Denmark; November 5, 2024 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief Executive Officer , Jan van de Winkel, Ph.D. and C hief F inancial O fficer , Anthony Pagano will take part [...]

Molecular Health Technologies Named Supplement Manufacturing Company of the Year by Food Business Review

05/11/2024 - 20:46

Delivering Tailored Solutions with Innovative Products and Advanced Technologies MILBURN, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Molecular Health Technologies (MHT) , a leader in custom supplement manufacturing, has [...]

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

05/11/2024 - 15:27

Tevogen Bio begins pre-clinical effort for TVGN 920, signaling the start of its oncology treatment pipeline. Tevogen Bio created a data set containing known proteins in the HPV genome to identify targets, accelerating [...]

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

05/11/2024 - 15:30

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid [...]

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

05/11/2024 - 15:55

- Presentation at ASH will Feature Results from the Phase 2a Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia After Venetoclax Failure – - 50% Response Rate at the Selected Dose Level of 30 mg Twice a Week [...]

Markham Fertility Centre Heads North to Barrie-Innisfil, Orillia, and Sudbury, Bringing Fertility Care Closer to Home for Northern Ontario

05/11/2024 - 16:21

Markham Fertility Centre (MFC) MARKHAM, Ontario, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Time, cost, and distance are barriers that prevent many from accessing fertility care and achieving their family-building goals. We are [...]

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

05/11/2024 - 18:00

Media Release COPENHAGEN, Denmark; November 5, 2024 More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin’s lymphoma (NHL) patients New [...]

Press Release Biocartis NV: Biocartis appoints Randy Polonsky as Chief Financial Officer

05/11/2024 - 18:20

PRESS RELEASE - 05/11/2024, 18:15 CET Biocartis appoints Randy Polonsky as Chief Financial Officer Mechelen, Belgium, 05 November 2024 – Biocartis NV (“Biocartis”), an innovative molecular diagnostics company, announces [...]

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program

05/11/2024 - 14:30

SOLANA BEACH, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]